Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 9/2011

01-09-2011 | Original Article

Use of unnecessary medications by patients with advanced cancer: cross-sectional survey

Authors: Angelo Fede, Michele Miranda, Daniella Antonangelo, Ligia Trevizan, Henrique Schaffhausser, Bruno Hamermesz, Camile Zimmermann, Auro Del Giglio, Rachel P. Riechelmann

Published in: Supportive Care in Cancer | Issue 9/2011

Login to get access

Abstract

Background

Cancer patients at the end of life take numerous medications. However, it has not been assessed what proportion of patients take unnecessary medications and which patients are at risk for doing so.

Methods

Cross-sectional survey of medications utilized by terminally ill ambulatory cancer patients, with the aim of identifying medications considered unnecessary as per explicit criteria. The criteria took into account whether drugs could benefit patients with terminal cancer.

Results

Among 87 patients, 21 (24%, 95% confidence interval [CI] 15.6–34.5%) were taking at least one unnecessary medication, the most common being gastric protectors. In multivariable analyses, patients with Charlson Comobidity Index ≤ 1 (OR: 4.49, CI95% 1.32–15.26; p = 0.01) or whose medication list had not been reconciled by physicians (OR: 6.38, CI95% 1.21–33.40; p = 0.02) were more likely to use an unnecessary medication.

Conclusion

Patients with advanced cancer take many medications considered unnecessary. Medication reconciliation should be performed routinely for these patients.
Literature
1.
2.
Honegger HP (1991) Avoiding futility: assessment of cancer patients in intensive care units. Ann Oncol 2(8):530–531PubMed
3.
von Gruenigen VE, Daly BJ (2005) Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol 97(2):638–644CrossRef
4.
5.
Burt RA (2002) The medical futility debate: patient choice, physician obligation, and end-of-life care. J Palliat Med 5(2):249–254PubMedCrossRef
6.
Cantor MD, Braddock CH 3rd, Derse AR et al (2003) Do-not-resuscitate orders and medical futility. Arch Intern Med 163(22):2689–2694PubMedCrossRef
7.
Kasman DL (2004) When is medical treatment futile? A guide for students, residents, and physicians. J Gen Intern Med 19(10):1053–1056PubMedCrossRef
8.
Khatcheressian J, Harrington SB, Lyckholm LJ, Smith TJ (2008) 'Futile care': what to do when your patient insists on chemotherapy that likely won't help. Oncology (Williston Park) 22(8):881–888, discussion 893, 896, 898
9.
Riechelmann RP, Krzyzanowska MK, Zimmermann C (2009) Futile medication use in terminally ill cancer patients. Support Care Cancer 17(6):745–748PubMedCrossRef
10.
Riechelmann RP, Krzyzanowska MK, O'Carroll A, Zimmermann C (2007) Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer 15(12):1407–1412PubMedCrossRef
11.
Currow DC, Stevenson JP, Abernethy AP, Plummer J, Shelby-James TM (2007) Prescribing in palliative care as death approaches. J Am Geriatr Soc 55(4):590–595PubMedCrossRef
12.
Riechelmann RP, Zimmermann C, Chin SN et al (2008) Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage 35(5):535–543PubMedCrossRef
13.
Corcoran ME (1997) Polypharmacy in the older patient with cancer. Cancer Control 4(5):419–428PubMed
14.
Riechelmann RP, Del Giglio A (2009) Drug interactions in oncology: how common are they? Ann Oncol 20:1907–1912PubMedCrossRef
15.
Glare P, Virik K, Jones M et al (2003) A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 327(7408):195–198PubMedCrossRef
16.
Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655PubMedCrossRef
17.
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRef
18.
Curtis EB, Walsh TD (1993) Prescribing practices of a palliative care service. J Pain Symptom Manage 8(5):312–316PubMedCrossRef
19.
Mercadante S, Fulfaro F, Casuccio A (2001) Pattern of drug use by advanced cancer patients followed at home. J Palliat Care 17(1):37–40PubMed
20.
Nauck F, Ostgathe C, Klaschik E et al (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18(2):100–107PubMedCrossRef
21.
Nicholson A, Andrew I, Etherington R, Gamlin R, Lovel T, Lloyd J. (2001) Futile and inappropriate prescribing: an assessment of the issue in a series of patients admitted to a palliative care unit. The International Journal of Pharmacy Practice (September issue):71
22.
Kite S, Wilkinson S (2002) Beyond futility: to what extent is the concept of futility useful in clinical decision-making about CPR? Lancet Oncol 3(10):638–642PubMedCrossRef
23.
Vollrath AM, Sinclair C, Hallenbeck J (2005) Discontinuing cardiovascular medications at the end of life: lipid-lowering agents. J Palliat Med 8(4):876–881PubMedCrossRef
24.
Samano ES, Ribeiro LM, Campos AS et al (2005) Use of complementary and alternative medicine by Brazilian oncologists. Eur J Cancer Care (Engl) 14(2):143–148CrossRef
25.
Basu TK (1985) Drug–vitamin interaction. Int J Vitam Nutr Res Suppl 27:247–258PubMed
Metadata
Title
Use of unnecessary medications by patients with advanced cancer: cross-sectional survey
Authors
Angelo Fede
Michele Miranda
Daniella Antonangelo
Ligia Trevizan
Henrique Schaffhausser
Bruno Hamermesz
Camile Zimmermann
Auro Del Giglio
Rachel P. Riechelmann
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 9/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0947-1

Other articles of this Issue 9/2011

Supportive Care in Cancer 9/2011 Go to the issue

Original Article

Individualized pharmacological treatment of oral mucositis pain in patients with head and neck cancer receiving radiotherapy

Original Article

The post-treatment experience of cancer survivors with pre-existing cardiopulmonary disease

Original Article

Self-reported fatigue: one dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy—Fatigue (FACIT-F) questionnaire

Original Article

Characterization of cancer-induced bone pain: an exploratory study

Original Article

A qualitative assessment of upper quarter dysfunction reported by physical therapists treated for breast cancer or treating breast cancer sequelae

Original Article

Insomnia in elderly cancer survivors—a population-based controlled study of associations with lifestyle, morbidity, and psychosocial factors. Results from the Health Survey of North-Trøndelag County (HUNT-2)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits